BFRI Biofrontera Forecast, Technical & Fundamental Analysis
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy... Show more
BFRI is expected to report earnings to fall 65.85% to -14 cents per share on August 07
Q2'26
Est.
$-0.14
Q1'26
Missed
by $0.35
Q4'25
Beat
by $0.07
Q3'25
Missed
by $0.05
Q2'25
Est.
$-0.57
The last earnings report on May 14 showed earnings per share of -40 cents, missing the estimate of -5 cents. With 294.25K shares outstanding, the current market capitalization sits at 14.98M.
A.I.dvisor tells us that BFRI and ACET have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BFRI and ACET's prices will move in lockstep.
BFRI's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for BFRI moved out of overbought territory on July 31, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BFRI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BFRI broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on BFRI as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BFRI just turned positive on July 30, 2026. Looking at past instances where BFRI's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
BFRI moved above its 50-day moving average on July 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BFRI crossed bullishly above the 50-day moving average on June 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BFRI advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 118 cases where BFRI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.468) is normal, around the industry mean (47.256). P/E Ratio (0.888) is within average values for comparable stocks, (103.786). BFRI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.832). BFRI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (0.295) is also within normal values, averaging (115.273).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BFRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
